Amendments to the Claims

This listing will replace all prior versions, and listings, of claims in the application:

Claims 1-47 (cancelled).

Claim 48 (currently amended): Improved multiparticulate tablet which disintegrates in contact with the saliva in the mouth in less than 40 seconds, comprising ~~wherein it is based on~~ particles of coated active substance ~~principle which have intrinsic compression characteristics~~, and [[on]] a mixture of excipients being free of effervescent agents, [[and]] the ratio of excipient mixture to coated active ~~principle~~ substance particles being 0.4 to 6 parts by weight, the mixture of excipients comprising: 1 to 15% by weight based on the weight of the tablet of a disintegration agent selected from the group consisting of croscarmellose, crospovidone and mixtures thereof; 30 to 90% by weight, based on the weight of the tablet of a soluble diluent agent with binding properties which consists of a directly compressible polyol selected from the group consisting of mannitol, xylitol and maltitol ~~having less than 13 carbon atoms,~~ with an average particle diameter of 100 to 500 µm;0.05 to 2% by weight based on the weight of the tablet of a lubricant selected from the group consisting of magnesium stearate, sodium stearyl flumarate, stearic acid, micronized polyoxyethylene glycol and mixtures thereof; at least one from the group consisting of sweeteners, flavorings, colors and mixtures thereof; and 0.1 to 10% by weight based on the weight of the tablet of a permeabilizing agent selected from the group consisting of precipitated silicas with a high affinity for aqueous solvents, maltodextrins, β-cyclodextrines and mixtures thereof~~, the proportion of disintegration agent being 1 to 15% by weight and the proportion of soluble agent being 30 to 90% by weight, based in each case on the weight of the tablet~~.

Claims 49-50 (canceled).

Claim 51 (currently amended): Improved multiparticulate tablet according to claim 48, wherein the ratio of excipient mixture to coated active substance ~~principle~~ is 1 to 4 parts by weight.

Claim 52 (previously presented): Tablet according to claim 48, wherein the proportion of disintegration agent is 2 to 7% by weight and the proportion of soluble agent is 40 to 70% based in each case on the weight of the tablet.

Claim 53 (currently amended): Tablet according to claim 48, wherein the active substance ~~principle~~ is selected from the group consisting of aspirin, paracetamol and ibuprofen.

Claims 54-57 (canceled).

Claim 58 (previously presented): Tablet according to claim 48, wherein the proportion of permeabilizing agent is 0.5 to 5% based on the weight of the tablet.

Claim 59 (canceled).

Claim 60 (currently amended): Tablet according to claim [[49]]48, wherein the sweetener is selected from the group consisting of aspartame, potassium acesulfame, sodium saccharinate, neohesperidin dihydrochalcone and mixtures thereof.

Claim 61 (currently amended): Improved multiparticulate tablet which disintegrates in contact with the saliva in the mouth in less than 40 seconds, comprising ~~wherein it is based on~~ particles of coated active substance ~~principle which have intrinsic compression characteristics,~~ and [[on]] a mixture of excipients being free of effervescent agents, [[and]] the ratio of excipient mixture to coated active ~~principle~~ substance particles being 0.4 to 6 parts by weight, the mixture of excipients comprising: 1 to 15% by weight based on the weight of the tablet of a disintegration agent selected from the group consisting of croscarmellose, crospovidone and mixtures thereof; 30 to 90% by weight, based on the

weight of the tablet of a at least two soluble diluent agents with binding properties which consists of a polyol selected from the group consisting of mannitol, xylitol , sorbitol and maltitol ~~having less than 13 carbon atoms~~ and at least one diluent agent being in the form of the directly compressible product with an average particle diameter of 100 to 500 μm, and at least one diluent agent being in the form of a powder with an average particle diameter of less than 100μm, the ratio of directly compressible polyol to powder polyol being 99/1 to 20/80; 0.05 to 2% by weight based on the weight of the tablet of a lubricant selected from the group consisting of magnesium stearate, sodium stearyl fumarate, stearic acid, micronized polyoxyethylene glycol and mixtures thereof; at least one from the group consisting of sweeteners, flavorings, colors and mixtures thereof; and 0.1 to 10% by weight based on the weight of the tablet of a permeabilizing agent selected from the group consisting of precipitated silicas with a high affinity for aqueous solvents, maltodextrins, β-cyclodextrines and mixtures thereof ~~the proportion of disintegration agent being 1 to 15% by weight and the proportion of soluble agent being 30 to 90% by weight, based in each case on the weight of the tablet~~.

Claims 62-63 (canceled).

Claim 64 (currently amended): Improved multiparticulate tablet according to claim 61, wherein the ratio of excipient mixture to coated active substance ~~principle~~ is 1 to 4 parts by weight.

Claim 65 (previously presented): Improved multiparticulate tablet according to claim 61, wherein the proportion of directly compressible polyol to powder polyol is 80/20 to 20/80.

Claim 66 (previously presented): Tablet according to claim 61, wherein the proportion of disintegration agent is 2 to 7% by weight and the proportion of soluble agent is 40 to 70% based in each case on the weight of the tablet.

67 (currently amended): Tablet according to claim 61, wherein the active substance ~~principle~~ is selected from the group consisting of aspirin, paracetamol and ibuprofen.

Claims 68-71 (canceled).

72 (currently amended): Tablet according to claim [[71]]61, wherein the proportion of permeabilizing agent is 0.5 to 5% based on the weight of the tablet.

Claim 73 (canceled).

74 (currently amended): Tablet according to claim [[62]]61, wherein the sweetener is selected from the group consisting of aspartame, potassium acesulfame, sodium saccharinate, neohesperidin dihydrochalcone and mixtures thereof.